PofoliaShared via Pofolia

European Respiratory Journal· 2020Q1

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Wei-Jie Guan, Wenhua Liang, Yi Zhao, Heng-rui Liang et al.

Short summary

COVID-19 patients with at least one comorbidity were 79% more likely to require ICU admission, ventilation, or death, while those with two or more comorbidities faced a 159% increased risk, according to a nationwide analysis of 1590 patients in China.

AI-generated from the title and abstract; the full text is not read.

Key points

  • 1590 COVID-19 patients from 575 hospitals across China were analyzed.
  • 13.2% of patients reached composite endpoints (ICU, ventilation, or death).
  • Patients with at least one comorbidity had a 1.79 hazard ratio for severe outcomes.
  • Patients with two or more comorbidities had a 2.59 hazard ratio for severe outcomes.
  • COPD, diabetes, hypertension, and malignancy were identified as specific risk factors.

AI-generated from the title and abstract; the full text is not read.

Abstract

BACKGROUND: The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide. OBJECTIVE: To evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status. METHODS: We analysed data from 1590 laboratory confirmed hospitalised patients from 575 hospitals in 31 provinces/autonomous regions/provincial municipalities across mainland China between 11 December 2019 and 31 January 2020. We analysed the composite end-points, which consisted of admission to an intensive care unit, invasive ventilation or death. The risk of reaching the composite end-points was compared according to the presence and number of comorbidities. RESULTS: The mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424-5.048)), diabetes (1.59 (1.03-2.45)), hypertension (1.58 (1.07-2.32)) and malignancy (3.50 (1.60-7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16-2.77) among patients with at least one comorbidity and 2.59 (1.61-4.17) among patients with two or more comorbidities. CONCLUSION: Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.

The authors' abstract, as published at the source. European Respiratory Journal, 2020 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Infectious Diseases

Infectious DiseasesMedicine